SCHEMBL25747720

SCHEMBL25747720

O=C(CCCl)NCc1nn(-c2ccccc2)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RARG P13631 1/20 0.47
▸ RORC P51449 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ TEAD1 P28347 1/20 0.41
▸ TEAD4 Q15561 1/20 0.41
▸ TEAD2 Q15562 1/20 0.41
▸ TEAD3 Q99594 1/20 0.41
▸ P2RX7 Q99572 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ MALT1 Q9UDY8 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25747721 0.91 RARG (0.48) RARGRORCADORA3GAAALDH1A1
SCHEMBL25750434 0.85 TEAD1 (0.62) RARGRORCSMN1; SMN2TEAD1TEAD4
SCHEMBL25747719 0.80 RARG (0.45) RARGRORCADORA3CYP2C19ALDH1A1
SCHEMBL25237436 0.76 TEAD1 (0.66) RARGRORCSMN1; SMN2TEAD1TEAD4
SCHEMBL30431649 0.76 TEAD1 (0.66) RARGRORCSMN1; SMN2TEAD1TEAD4
Beclamide SCHEMBL35199 0.75 GAA (0.72) CYP3A4CYP2C19L3MBTL1GAAALDH1A1
SCHEMBL25231312 0.74 RORC (0.45) RARGRORCADORA3CYP2C19ALDH1A1
SCHEMBL25278823 0.74 CCR1 (0.48) RARGRORCL3MBTL1TEAD1TEAD4
SCHEMBL25274909 0.74 LMNA (0.50) RARGRORCTEAD1TEAD4TEAD2
SCHEMBL7658230 0.74 LMNA (0.45) RARGRORCADORA3CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202984-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE VHL, TP53, MCL1 RARG 457/4885RORC 240/4885ADORA3 2641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback